Literature DB >> 10438807

Transcript initiation and 5'-end modifications are separable events during vesicular stomatitis virus transcription.

E A Stillman1, M A Whitt.   

Abstract

In this report we describe a novel, bipartite vesicular stomatitis virus (VSV) replication system which was used to study the effect of mutations in the transcription start sequence on transcript initiation and 5'-mRNA modifications. The bipartite replication system consisted of two genomic RNAs, one of which (VSVDeltaG) was a recombinant VSV genome with the G gene deleted and the other (GFC) contained the G gene and two non-VSV reporter genes (green fluorescent protein [GFP] and chloramphenicol acetyltransferase [CAT]). Coinfection of cells with these two components resulted in high-level virus production and gave titers similar to that from wild-type-VSV-infected cells. Mutations were introduced within the first 3 nucleotides of the transcription start sequence of the third gene (CAT) of GFC. The effects of these changes on the synthesis and accumulation of CAT transcripts during in vivo transcription (e.g., in infected cells), and during in vitro transcription were determined. As we had reported previously (E. A. Stillman and M. A. Whitt, J. Virol. 71:2127-2137, 1997), changing the first and third nucleotides (NT-1 and NT-3) reduced CAT transcript levels in vivo to near undetectable levels. Similarly, changing NT-2 to a purine also resulted in the detection of very small amounts of CAT mRNA from infected cells. In contrast to the results in vivo, the NT-1C mutant and all of the second-position mutants produced near-wild-type amounts of CAT mRNA in the in vitro system, indicating that the mutations did not prevent transcript initiation per se but, rather, generated transcripts that were unstable in vivo. Oligo (dT) selection and Northern blot analysis revealed that the transcripts produced from these mutants did not contain a poly(A)(+) tail and were truncated, ranging in size from 40 to 200 nucleotides. Immunoprecipitation analysis of cDNA-RNA hybrids with an antibody that recognizes trimethylguanosine revealed that the truncated mutant transcripts were not properly modified at the 5' end, indicating the transcripts either were not capped or were not methylated. This is the first demonstration that transcript initiation and capping/methylation are separable events during VSV transcription. A model is proposed in which polymerase processivity is linked to proper 5'-end modification. The model suggests that a proofreading mechanism exists for VSV and possibly other nonsegmented minus-strand RNA viruses, whereby if some transcripts do not become capped during transcription in a normal infection, a signal is transduced such that the polymerase undergoes abortive elongation and the defective transcript is terminated prematurely and subsequently degraded.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438807      PMCID: PMC104244     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Site on the vesicular stomatitis virus genome specifying polyadenylation and the end of the L gene mRNA.

Authors:  M Schubert; J D Keene; R C Herman; R A Lazzarini
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

2.  Intergenic sequences of the vesicular stomatitis virus genome (New Jersey serotype): evidence for two transcription initiation sites within the L gene.

Authors:  D Luk; P S Masters; D S Gill; A K Banerjee
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Characterization of the infections of permissive and nonpermissive cells by host range mutants of vesicular stomatitis virus defective in RNA methylation.

Authors:  S M Horikami; F De Ferra; S A Moyer
Journal:  Virology       Date:  1984-10-15       Impact factor: 3.616

5.  Host range mutants of vesicular stomatitis virus defective in in vitro RNA methylation.

Authors:  S M Horikami; S A Moyer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Sequential synthesis of 5'-proximal vesicular stomatitis virus mRNA sequences.

Authors:  L E Iverson; J K Rose
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

7.  RNA polymerase-associated interactions near template promoter sequences of defective interfering particles of vesicular stomatitis virus.

Authors:  C L Isaac; J D Keene
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

8.  Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.

Authors:  L E Iverson; J K Rose
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

9.  Identification of promoter-proximal oligonucleotides and a unique dinucleotide, pppGpC, from in vitro transcription products of vesicular stomatitis virus.

Authors:  P K Chanda; A K Banerjee
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

10.  Identification of a set of proteins (C' and C) encoded by the bicistronic P gene of the Indiana serotype of vesicular stomatitis virus and analysis of their effect on transcription by the viral RNA polymerase.

Authors:  R W Peluso; J C Richardson; J Talon; M Lock
Journal:  Virology       Date:  1996-04-15       Impact factor: 3.616

View more
  46 in total

1.  Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release.

Authors:  H R Jayakar; K G Murti; M A Whitt
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression.

Authors:  Gail W Wertz; Robin Moudy; L Andrew Ball
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  Transcription and replication initiate at separate sites on the vesicular stomatitis virus genome.

Authors:  Sean P J Whelan; Gail W Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

4.  Competition between the Sendai virus N mRNA start site and the genome 3'-end promoter for viral RNA polymerase.

Authors:  Philippe Le Mercier; Dominique Garcin; Eduardo Garcia; Daniel Kolakofsky
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

Authors:  Michael Garbutt; Ryan Liebscher; Victoria Wahl-Jensen; Steven Jones; Peggy Möller; Ralf Wagner; Viktor Volchkov; Hans-Dieter Klenk; Heinz Feldmann; Ute Ströher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 6.  An unconventional pathway of mRNA cap formation by vesiculoviruses.

Authors:  Tomoaki Ogino; Amiya K Banerjee
Journal:  Virus Res       Date:  2011-09-16       Impact factor: 3.303

7.  Identification of internal sequences in the 3' leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity.

Authors:  David R McGivern; Peter L Collins; Rachel Fearns
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Polymerase slippage at vesicular stomatitis virus gene junctions to generate poly(A) is regulated by the upstream 3'-AUAC-5' tetranucleotide: implications for the mechanism of transcription termination.

Authors:  J N Barr; G W Wertz
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Opposing effects of inhibiting cap addition and cap methylation on polyadenylation during vesicular stomatitis virus mRNA synthesis.

Authors:  Jianrong Li; Amal Rahmeh; Vesna Brusic; Sean P J Whelan
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Transcriptional Regulation in Ebola Virus: Effects of Gene Border Structure and Regulatory Elements on Gene Expression and Polymerase Scanning Behavior.

Authors:  Kristina Brauburger; Yannik Boehmann; Verena Krähling; Elke Mühlberger
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.